Detalles de la búsqueda
1.
A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis.
Oncologist
; 28(12): e1268-e1278, 2023 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37343145
2.
Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab.
Osteoarthritis Cartilage
; 31(12): 1612-1626, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37652258
3.
Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis.
BMC Musculoskelet Disord
; 23(1): 106, 2022 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35105318
4.
Factors associated with physician-reported treatment status of patients with osteoarthritis pain.
BMC Musculoskelet Disord
; 23(1): 498, 2022 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35619074
5.
Burden of chronic low back pain: Association with pain severity and prescription medication use in five large European countries.
Pain Pract
; 22(3): 359-371, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34780102
6.
Are pain severity and current pharmacotherapies associated with quality of life, work productivity, and healthcare utilisation for people with osteoarthritis in five large European countries?
Clin Exp Rheumatol
; 39(4): 819-828, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32896256
7.
Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.
Int J Clin Pract
; 75(12): e14975, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34626502
8.
Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study.
Surg Technol Int
; 38: 467-477, 2021 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34043229
9.
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Ann Rheum Dis
; 79(6): 800-810, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32234715
10.
Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study.
Int J Urol
; 26(2): 192-200, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30362173
11.
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
JAMA
; 322(1): 37-48, 2019 07 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31265100
12.
Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera.
Ann Rheum Dis
; 81(4): e66, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32424029
13.
Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
BJU Int
; 119(5): 793-803, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27988986
14.
Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia integrated data from 1,499 study participants.
BJU Int
; 115(5): 815-21, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25195970
15.
Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
J Sex Med
; 12(1): 129-38, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25353053
16.
Predictors of self-reported benign prostatic hyperplasia in European men: analysis of the European National Health and Wellness Survey.
World J Urol
; 33(5): 639-47, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25100623
17.
Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
Int J Urol
; 22(6): 582-7, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25827166
18.
Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies.
Int J Urol
; 22(4): 378-84, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25711404
19.
Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
J Urol
; 191(4): 1045-50, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24445278
20.
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
J Urol
; 191(3): 727-33, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24096118